DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company ...

DBV Technologies (NASDAQ:DBVT – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect DBV Technologies to post earnings of ($0.31) ...

AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 ...

DBV Technologies has made significant strides in its clinical trial program for Viaskin Peanut. The Phase 3 VITESSE trial, targeting children aged 4-7 years, has completed its screening phase and ...

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment ...

What initially drew you to the field of allergy and immunology, and how did your focus come to centre on food allergic ...

Investment analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “hold” rating on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...